scholarly journals DCP1A is an unfavorable prognostic-related enhancer RNA in hepatocellular carcinoma

Aging ◽  
2021 ◽  
Author(s):  
Hao Wu ◽  
Jinrui Zhang ◽  
Yi Bai ◽  
Sai Zhang ◽  
Zhixin Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Enhancer Rna

scholarly journals SPRY4-AS1, A Novel Enhancer RNA, Is a Potential Novel Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Mu Ye ◽  
Sheng Wang ◽  
Jing-bo Qie ◽  
Pei-long Sun
Keyword(s):  
Hepatocellular Carcinoma ◽  
Therapeutic Target ◽  
The Cancer Genome Atlas ◽  
Lower Grade ◽  
Hippo Signaling ◽  
Enhancer Rna ◽  
Papillomavirus Infection ◽  
Potential Biomarker ◽  
Cancer Genome Atlas ◽  
Tumor Types

A growing number of evidence have demonstrated the involvement of enhancer RNAs (eRNAs) in tumor progression. However, the possible functions of eRNAs in hepatocellular carcinoma (HCC) remain largely unclear. Our present research aimed to screen critical eRNAs and to further delve into the clinical significance of eRNAs in HCC patients. In this study, we identified 124 prognosis-related eRNAs by analyzing The Cancer Genome Atlas (TCGA) datasets. Among them, SPRY4 antisense RNA 1 (SPRY4-AS1) may be a key eRNA involved in HCC progression. SPRY4 was a regulatory target of SPRY4-AS1. High SPRY4-AS1 expression was associated with poor prognosis of HCC patients. Kyoto Encyclopedia of Genes and Genomes (KEGG) assays revealed that the mainly enriched biological process included Human papillomavirus infection, Hippo signaling pathway, and Proteoglycans in cancer. Besides, RT-PCR and immunohistochemical staining confirmed SPRY4-AS1 as an overexpressed eRNA in HCC specimens. The pan-cancer assays revealed that SPRY4-AS1 was associated with glioblastoma multiforme (GBM), adrenocortical carcinoma (ACC), brain lower grade glioma (LGG) and mesothelioma(MESO). Positive associations were observed between SPRY4-AS1 and SPRY4 (its target gene) in 16 tumor types. Collectively, our findings reveal a novel eRNA SPRY4-AS1 for HCC progression and suggest that SPRY4-AS1 may be a potential biomarker and therapeutic target for HCC.

Multimodality treatment of hepatocellular carcinoma

1998 ◽  
Vol 13 (11-s4) ◽  
pp. S315-S319 ◽  
Author(s):  
ZHAO-YOU TANG ◽  
XIN-DA ZHOU ◽  
ZENG-CHEN MA ◽  
ZHI-QUAN WU ◽  
JIA FAN ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Multimodality Treatment

Hepatocellular carcinoma

1982 ◽  
Vol 118 (1) ◽  
pp. 69-70 ◽  
Author(s):  
A. J. Bennett
Keyword(s):  
Hepatocellular Carcinoma

Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplanation

2001 ◽  
Vol 120 (5) ◽  
pp. A90-A90
Author(s):  
N ESNAOLA ◽  
G LAUWERS ◽  
N MIRZA ◽  
D NAGORNEY ◽  
D DOHERTY ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Microvascular Invasion

Serum and tissue PIVKA-II expression reflect the biological malignant potential of small hepatocellular carcinoma

2001 ◽  
Vol 120 (5) ◽  
pp. A558-A558
Author(s):  
M TAMANO ◽  
K KOJIMA ◽  
M OGUMA ◽  
M LIJIMA ◽  
T MUROHISA ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Malignant Potential ◽  
Small Hepatocellular Carcinoma

Intraoperative abdominal ultrasonography-guided large volume ethanol injection for hepatocellular carcinoma

2001 ◽  
Vol 120 (5) ◽  
pp. A482-A482
Author(s):  
R MONDRAGONSANCHEZ ◽  
A GARDUOLOPEZ ◽  
H MURRIETA ◽  
M FRIASMENDIVIL ◽  
R ESPEJO ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Large Volume ◽  
Abdominal Ultrasonography ◽  
Ethanol Injection
Sign in / Sign up

Export Citation Format

Share Document